Highlights

  • Island Pharmaceuticals shares rose 1.37% to AUD 0.37 during the morning session on 16 June 2026.
  • The company presented new analysis from its PROTECT dengue study at the 9th Asia Dengue Summit in Singapore.
  • ISLA-101 achieved target plasma concentrations and demonstrated antiviral activity during the Phase 2a PROTECT study.
  • Positive top-line results supported continued development of ISLA-101 for both dengue prevention and treatment.
  • Island is advancing discussions with potential strategic partners regarding future Phase 2 and Phase 3 clinical studies.

Island Pharmaceuticals Limited (ASX:ILA) recorded a modest gain during the morning session on 16 June 2026, with shares rising 1.37% to AUD 0.37 after the company released an investor presentation linked to the 9th Asia Dengue Summit in Singapore.

The presentation, delivered by Chief Executive Officer and Managing Director Dr David Foster, outlined new analysis from the company's completed PROTECT clinical study and provided investors with an update on the development pathway for ISLA-101, Island's lead dengue-focused antiviral candidate.

While the day's move was relatively modest, Island Pharmaceuticals has delivered a markedly different performance over a longer period. The stock remains up 117.65% over the past year, reflecting continued investor interest in the company's infectious disease portfolio and clinical development programs.

About Island Pharmaceuticals

Island Pharmaceuticals is an Australian antiviral drug development company focused on diseases where treatment options remain limited or where significant public health threats continue to exist.

The company is advancing two clinical-stage antiviral programs, ISLA-101 and Galidesivir, both targeting infectious diseases with substantial unmet medical needs.

ISLA-101 is being developed primarily for dengue fever and other mosquito-borne viral diseases, while Galidesivir is being investigated for a broad range of viral infections including Ebola, Marburg, MERS, Zika and Yellow Fever.

Island's strategy centres on advancing therapies that address urgent viral disease threats while pursuing clinical and regulatory milestones that may support future commercialisation opportunities.

New PROTECT Study Analysis Presented at Asia Dengue Summit

The company's latest announcement centred on its participation at the 9th Asia Dengue Summit held in Singapore.

According to Island Pharmaceuticals, the presentation included new analysis from the completed PROTECT study, which has been evaluating ISLA-101 in dengue.

The summit provided an opportunity for the company to share additional insights into the program's clinical findings and ongoing development plans.

While the announcement itself was focused on the presentation, the accompanying investor materials provided a broader overview of clinical outcomes, future development pathways and the rationale supporting continued advancement of ISLA-101.

The update comes as dengue continues to represent a significant public health challenge across many regions of Asia and other tropical areas around the world.

ISLA-101 Remains the Centrepiece of the Dengue Program

ISLA-101 is a clinical-stage antiviral candidate that Island Pharmaceuticals is developing for the prevention and treatment of dengue fever.

The drug has an established safety profile, having previously been evaluated across 48 human clinical studies in other indications before being repurposed for dengue and related mosquito-borne diseases.

According to the company, laboratory and animal studies have demonstrated broad antiviral activity against several flaviviruses, including dengue, Zika, Yellow Fever and West Nile virus.

Island highlighted that ISLA-101 showed potent anti-dengue activity in laboratory studies using fresh human cells and demonstrated protective effects in animal models of dengue and Zika infection.

The company also reported that increasing concentrations of ISLA-101 improved survival outcomes in severe dengue animal models, with two daily doses preventing approximately 70% of deaths in otherwise lethal infection models.

These findings continue to support the scientific rationale behind the ongoing clinical development program.

PROTECT Study Reached Key Milestones

A significant portion of the presentation focused on outcomes from the PROTECT clinical study.

The trial was designed as a proof-of-concept study using a dengue human infection model and included both preventative and treatment cohorts.

In the preventative cohort, participants received ISLA-101 before infection exposure, while the treatment cohort evaluated the drug after infection had occurred.

According to Island, a Safety Review Committee concluded that administration of ISLA-101 was safe and that participants achieved the desired blood concentrations of the drug.

The committee also observed evidence of antiviral activity compared with control subjects.

These findings supported progression from the preventative stage into the treatment component of the study.

The company noted that additional data analysis remains ongoing, with further information expected through future scientific publications.

Positive Top-Line Results Support Further Development

Among the key messages presented at the summit was Island's view that the study generated encouraging results supporting continued clinical development.

The company reported that the trial successfully achieved targeted plasma concentrations of ISLA-101.

Top-line findings indicated meaningful reductions in viral load and symptoms among participants in the preventative cohort.

Within the treatment cohort, Island observed signals consistent with drug activity, including a negative correlation between the timing of viral development and peak viral levels.

The company believes these outcomes provide support for advancing ISLA-101 into future studies focused on both prevention and treatment settings.

Management stated that efforts are already underway to optimise oral formulations for preventative use and intravenous formulations for treatment applications.

Understanding the Clinical Significance

One of the key measurements highlighted during the presentation involved viremia, which refers to the amount of virus circulating in the bloodstream.

According to Island, study data demonstrated reductions in viral load among treated participants, an outcome that may be relevant when evaluating therapeutic effectiveness against dengue infection.

The company also presented analyses examining RNAemia, viremia and NS1 biomarker data across study participants.

Additional findings indicated that earlier treatment with ISLA-101 was associated with lower cumulative viral levels in the treatment cohort.

These observations formed part of the broader dataset supporting ongoing development of the program.

However, the company did not announce any new clinical trial results beyond the analyses presented from the completed study.

Future Clinical and Regulatory Pathway Taking Shape

Beyond the clinical findings themselves, the investor presentation outlined potential next steps for the development program.

Island Pharmaceuticals described two potential development pathways depending on outcomes from ongoing analyses and future studies.

The company indicated that additional Phase 2 and Phase 3 clinical trials may be pursued in both preventative and treatment settings.

Future regulatory submissions would be expected to follow successful completion of later-stage studies.

Management also confirmed that engagement with the United States Food and Drug Administration (FDA) is expected to continue as development progresses.

These discussions may help define the most appropriate regulatory pathway for potential future approval.

Strategic Partner Discussions Continue

Another notable update involved the company's ongoing discussions with potential strategic partners.

Island stated that conversations are advancing with multiple parties regarding participation in future clinical studies.

While no new partnership agreements were announced, the company indicated that discussions are continuing around opportunities to support additional Phase 2 and Phase 3 development activities.

Strategic collaborations can often play an important role in clinical-stage biotechnology programs by providing expertise, funding support or commercialisation capabilities.

The company did not disclose details regarding the parties involved or the status of negotiations.

Galidesivir Provides Additional Pipeline Exposure

Although the primary focus of the presentation remained ISLA-101, Island also highlighted its second clinical-stage asset, Galidesivir.

The antiviral candidate has demonstrated activity against more than 20 RNA viruses, according to the company.

Target diseases include Ebola, Marburg, MERS, Zika and Yellow Fever, all of which continue to represent significant global health challenges.

Island noted that Galidesivir has received positive feedback from the FDA regarding the Animal Rule regulatory pathway and may also qualify for Priority Review Voucher opportunities.

The presence of a second development-stage asset provides additional diversification within the company's antiviral portfolio.

Dengue Remains a Significant Unmet Medical Need

The company's focus on dengue reflects the continuing need for new therapeutic options in the field.

Dengue is one of the world's most prevalent mosquito-borne viral diseases and continues to place pressure on healthcare systems across many tropical and subtropical regions.

Island's development strategy seeks to address both prevention and treatment opportunities through the ISLA-101 program.

The company believes the outcomes generated so far support further investigation of the drug candidate as it progresses through the development pathway.

With ongoing data analysis, potential future studies and regulatory engagement activities, the dengue program remains a central focus for management.

What This Means for Investors?

Island Pharmaceuticals' latest update was centred on new analysis from its completed PROTECT study, presented at the Asia Dengue Summit in Singapore. The company highlighted positive top-line findings, including evidence of antiviral activity, achievement of target drug concentrations and observations supporting continued development of ISLA-101.

The presentation also outlined future clinical and regulatory pathways, while confirming that discussions with potential strategic partners are continuing. Although the announcement did not include a new clinical trial result or commercial agreement, it provided investors with additional visibility into the progress of Island's dengue development program and the planned next steps for ISLA-101.